|Bid||43.62 x 900|
|Ask||43.74 x 900|
|Day's Range||40.59 - 43.85|
|52 Week Range||32.30 - 74.00|
|Beta (5Y Monthly)||2.72|
|PE Ratio (TTM)||37.07|
|Earnings Date||Apr 26, 2020 - Apr 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||74.46|
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $39.54, moving +1.49% from the previous trading session.
CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Directors at the Company’s upcoming annual general meeting to be held later this year. The Company also announced that Pablo Cagnoni, M.D., Chief Executive Officer of Rubius Therapeutics, will resign from the Board of Directors to focus on other commitments, effective immediately. “On behalf of our Board of Directors and management team, I would like to thank Pablo for his years of service and his many contributions to CRISPR Therapeutics, and I wish him the best in his future endeavors,” said Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1175.00% and 3.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics AG (CRSP) closed at $57.76 in the latest trading session, marking a +1.33% move from the prior day.
-Enrollment ongoing in clinical trials of CTX001™ for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110™, targeting CD19+.
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Can it continue?
CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day.
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
In 1998, the startup company Illumina launched a revolution in the life sciences industry by developing technology to slash the costs of identifying and mapping genetic material. Now, a little over 20 years later, Mammoth Biosciences is hoping to do the same thing for gene editing tools. The company, co-founded by Jennifer Doudna, who did some of the pioneering work to discover the gene editing enzyme known as CRISPR, has just raised $45 million as it looks to bring to market products that can be used not only for disease detection, but are more precise editing tools for genetic material.
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
Just months after its first product was approved by the FDA, Cambridge’s Acceleron Pharma is closer to executing a one-two punch after announcing new clinical trial data this week.
The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups.
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
If you look for mutual funds to invest in, 2019 was a blast. The S&P; 500's 2019 gain of 31.49% was the broad market's best since 2013's 32.39%.
Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.